Encodes An Animal Polypeptide Patents (Class 536/23.5)
-
Publication number: 20140363444Abstract: The present invention relates to anti-IL-23p19 binding compounds, in particular new humanized anti-IL-23p19 antibodies and therapeutic and diagnostic methods and compositions for using the same.Type: ApplicationFiled: June 12, 2014Publication date: December 11, 2014Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Rachel Rebecca BARRETT, Keith CANADA, Katrina Mary CATRON, Robert COPENHAVER, Lee Edward Frego, Ernest Lee Raymond, Sanjaya SINGH, Xiangyang ZHU
-
Publication number: 20140363878Abstract: The present invention relates to recombinant RNA virus templates derived from and applicable to negative strand naturally non-segmented viruses, including the families Bornaviridae, Filoviridae, and Paramyxoviridae, and methods for generating such recombinant RNA virus templates, wherein the templates are generated from two or more recombinant RNA molecules. The invention relates to the use of segmented recombinant RNA virus templates for naturally non-segmented RNA viruses to express heterologous gene products in appropriate host cell systems and/or to construct recombinant viruses taken from that family and that express, package, and/or present the heterologous gene product. The invention includes the expression products and recombinant and chimeric viruses thus prepared and vaccine and therapeutic formulations comprising the recombinant RNA viruses.Type: ApplicationFiled: March 11, 2014Publication date: December 11, 2014Inventors: Adolfo Garcia-Sastre, Peter Palese
-
Patent number: 8906365Abstract: The application relates to antimicrobial agents against Gram-negative bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and a peptide stretch fused to the enzyme at the N- or C-terminus, as well as pharmaceutical compositions thereof. Moreover, it relates to nucleic acid molecules encoding such a fusion protein, vectors carrying the nucleic acid molecules and host cells transformed with either the nucleic acid molecules or the vectors. In addition, it relates to such a fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means or as cosmetic substance. The application also relates to the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.Type: GrantFiled: June 28, 2010Date of Patent: December 9, 2014Assignees: Lysando AG, Katholieke Universiteit Leuven, K.U. Leuven R&DInventors: Rob Lavigne, Stefan Miller, Yves Briers, Guido Volckaert, Maarten Walmagh
-
Patent number: 8906676Abstract: Modified human four helical bundle (4HB) polypeptides and uses thereof are provided.Type: GrantFiled: January 28, 2005Date of Patent: December 9, 2014Assignee: Ambrx, Inc.Inventors: Ho Sung Cho, Thomas O. Daniel, Richard D. DiMarchi, Anna-Maria Hays, Troy E. Wilson, Bee-Cheng Sim, David C. Litzinger
-
Patent number: 8907072Abstract: The invention relates to inhibitors that bind to C5 and C5a, but which do not prevent the activation of C5 and do not prevent formation of or inhibit the activity of C5b. One example of such an inhibitor molecule is the monoclonal antibody designated MAb137-26, which binds to a shared epitope of human C5 and C5a. These inhibitors may be used to inhibit the activity of C5a in treating diseases and conditions mediated by excessive or uncontrolled production of C5a. The inhibitor molecules are also useful for diagnostic detection of the presence/absence or amount of C5 or C5a.Type: GrantFiled: February 5, 2013Date of Patent: December 9, 2014Assignee: Genentech, Inc.Inventors: Michael Fung, Meisheng Lu, William N. C. Sun, Cecily R. Y. Sun
-
Patent number: 8907055Abstract: There is presently provided mutant Sox2, Sox7 and Sox17 proteins that have acquired or increased ability to induce pluripotency in a partially differentiated or fully differentiated cell. Sox7 and Sox17 are mutated to resemble in part Sox2, or Sox2 is mutated to resemble in part Sox7 or Sox17. In one aspect, the Oct4 contact interface of Sox7 or Sox17 is mutated. In another aspect, the high mobility group (HMG) of Sox2 is fused to the C-terminal activation domain of Sox7 or Sox17. Methods relating to inducing pluripotency using a mutant Sox2, Sox7 or Sox17 protein are also provided.Type: GrantFiled: November 4, 2010Date of Patent: December 9, 2014Assignee: Agency for Science, Technology and ResearchInventors: Prasanna R. Kolatkar, Irene Aksoy, Ralf Jauch, Lawrence W. Stanton
-
Publication number: 20140356378Abstract: Uses of BMP-1 isoforms for diagnosing and treating defects and disorders of bone and soft tissues are described. Also described is a newly isolated variant of the BMP-1 isoform BMP-1-3.Type: ApplicationFiled: June 2, 2014Publication date: December 4, 2014Applicant: GENERA ISTRAZIVANJA d.o.oInventors: Slobodan VUKICEVIC, Lovorka GRGUREVIC, Boris MACEK
-
Publication number: 20140357578Abstract: Compositions, methods, and kits are provided for reduction of (CAG)n-RNA mediated toxicity. Compositions, methods, and kits are also provided for treatment of polyglutamine diseases.Type: ApplicationFiled: June 2, 2014Publication date: December 4, 2014Applicant: The Chinese University of Hong KongInventor: Ho Yin Edwin Chan
-
Publication number: 20140357704Abstract: Disclosed are variant RTEF-1 polypeptides having an RTEF-1 amino acid sequence with one or more internal deletions, wherein the polypeptides reduce VEGF promoter activity. Some of the RTEF-1 polypeptides include an amino acid sequence that is at least 80% identical to the contiguous amino acids of 1) amino acids 24 to 47 of SEQ ID NO:15 and 2) each of SEQ ID NOs:16 and 17, but does not comprise the contiguous amino acids of SEQ ID NOs:8, 9, 11, or 12. Also disclosed are nucleic acids encoding the variant RTEF-1 polypeptides of the present invention. Pharmaceutical compositions that include the polypeptides and nucleic acids of the present invention are also disclosed. Methods of inducing cell contact inhibition, regulating organ size, and reducing intracellular YAP activity are also set forth, as well as methods of treating hyperproliferative diseases such as cancer using the pharmaceutical compositions of the present invention.Type: ApplicationFiled: June 9, 2014Publication date: December 4, 2014Applicants: OREGON HEALTH & SCIENCE UNIVERSITY, RESEARCH DEVELOPMENT FOUNDATIONInventors: J. Timothy STOUT, Binoy APPUKUTTAN, Trevor MCFARLAND, Anna DYE
-
Publication number: 20140356361Abstract: This invention relates to repeated administration of antigen-specific immunotherapeutics using protocols, or elements thereof, that do not induce immunosuppression. In some embodiments, the protocol has been previously shown not to induce immunosuppression in a subject.Type: ApplicationFiled: June 4, 2014Publication date: December 4, 2014Applicant: Selecta Biosciences, Inc.Inventors: Roberto A. Maldonado, Takashi Kei Kishimoto
-
Publication number: 20140357565Abstract: Provided herein are methods and compositions for producing Factor VIII proteins. Such methods include introducing into a cell a nucleic acid molecule encoding a Factor VIII protein operably linked to a promoter, wherein the promoter is characterized by the ability to produce commercially viable Factor VIII protein; and incubating the cell under conditions for producing commercially viable Factor VIII protein. Also provided are nucleic acid molecules which encode a Factor VIII protein operably linked to a Chinese hamster elongation factor 1-a (CHEF1) promoter, which may be used in the methods provided herein.Type: ApplicationFiled: August 13, 2014Publication date: December 4, 2014Inventors: Randal J. KAUFMAN, Steven W. Pipe, Michael GRIFFITH
-
Publication number: 20140357564Abstract: The present invention relates to a polypeptide comprising a modified von Willebrand Factor (VWF) having a higher Factor VIII binding affinity than non-modified VWF, its pharmaceutical use and method of its preparation.Type: ApplicationFiled: February 14, 2013Publication date: December 4, 2014Inventors: Stefan Schulte, Thomas Weimer, Kay Hofmann
-
Patent number: 8901286Abstract: The present invention provides polypeptides with histone H3 lysine 79 methyltransferase activity as well as nucleic acids encoding the same. Also provided are methods of using the polypeptides and nucleic acids of the invention in screening assays to identify compounds of interest. Further provided are diagnostic methods for leukemia and prognostic methods to predict the course of the disease in a subject.Type: GrantFiled: October 14, 2008Date of Patent: December 2, 2014Assignee: The University of North Carolina at Chapel HillInventors: Yi Zhang, Qin Feng
-
Publication number: 20140349284Abstract: An object of the present invention is to provide a sample nucleic acid for single nucleotide polymorphism detection which is for use in a simple method for quickly detecting a single nucleotide polymorphism, PCR primers for preparation of a sample for single nucleotide polymorphism detection, and a sample for single nucleotide polymorphism detection which is for use in ion exchange chromatography analysis. The present invention provides a sample nucleic acid for single nucleotide polymorphism detection having the following features: (a) a full chain length of 200 bp or less; (b) a sequence (a tag sequence) incompletely complementary to a template DNA at the 5? or 3? end; and (c) a 10 bp or less difference in chain length from a sample nucleic acid to be compared with to determine the presence of a single nucleotide polymorphism.Type: ApplicationFiled: March 30, 2012Publication date: November 27, 2014Inventors: Takuya Yotani, Eiji Kiyotoh, Koji Ushizawa
-
Publication number: 20140348781Abstract: In certain embodiments, this disclosure relates to conjugates comprising GM-CSF and IL-9 and uses related thereto, e.g., enhancing the adaptive immune system. Typically the GM-CSF and IL-9 are connected by a polymer linker, e.g., polypeptide. In certain embodiments, the disclosure relates to nucleic acids encoding these polypeptide conjugates, vectors comprising nucleic acid encoding polypeptide conjugates, and protein expression systems comprising these vectors such as infectious viral particles and host cells comprising such a nucleic acids.Type: ApplicationFiled: May 20, 2014Publication date: November 27, 2014Applicants: CHILDREN'S HEALTHCARE OF ATLANTA, INC, EMORY UNIVERSITYInventors: Jacques Galipeau, Pingxin Li
-
Publication number: 20140349866Abstract: Methods are described for using genes crucial in TH17 differentiation, IL-12Rbeta 1/IL-23R, CCR6, BATF, AHR, STAT3 and IRF4 as new markers for rosacea. Also described, are methods of their use to diagnose rosacea, to screen inhibitors of Th17 differentiation. In particular, method are described for inhibiting at least one of these genes and using the screened inhibitors in rosacea treatment.Type: ApplicationFiled: June 25, 2012Publication date: November 27, 2014Applicant: GALDERMA RESEARCH & DEVELOPMENTInventor: Martin Steinhoff
-
Publication number: 20140348805Abstract: The present invention is directed to a high affinity T cell receptor (TCR) against a tumor-associated antigen, an isolated nucleic acid molecule encoding same, a T cell expressing said TCR, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing said tumor-associated antigen.Type: ApplicationFiled: March 25, 2014Publication date: November 27, 2014Applicant: Max-Delbrueck-Centrum fur Molekulare Medizin Berlin-BuchInventors: Dolores Jean Schendel, Susanne Wilde, Bernhard Frankenberger, Wolfgang Uckert
-
Publication number: 20140348859Abstract: Compositions of and methods for making and using alpha-1 antitrypsin (AAT) fusion molecules or peptide derivatives thereof are disclosed. The compositions and methods relate to generating an AAT fusion molecule of use in pharmaceutically acceptable compositions to treat a subject in need of AAT therapy or treatment. Compositions and methods disclosed herein concern linking AAT or derivative thereof to an immune fragment.Type: ApplicationFiled: January 10, 2013Publication date: November 27, 2014Applicants: KONKUK UNIVERSITY, OMNI BIO PHARMACEUTICAL, INC., THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATEInventors: Soohyun Kim, Charles A. Dinarello, James D. Crapo
-
Publication number: 20140350089Abstract: The present invention is directed to a synthetic nucleic acid sequence which encodes a protein wherein at least one non-common codon or less-common codon is replaced by a common codon. The synthetic nucleic acid sequence can include a continuous stretch of at least 90 codons all of which are common codons.Type: ApplicationFiled: March 3, 2014Publication date: November 27, 2014Applicant: SHIRE HUMAN GENETIC THERAPIES, INC.Inventors: Richard F. Selden, Allan M. Miller, Douglas A. Treco
-
Patent number: 8895263Abstract: Agents interfering with translocation of Toll-like receptor 3 (TLR3), methods of making and using the foregoing are disclosed.Type: GrantFiled: October 2, 2009Date of Patent: November 25, 2014Assignee: Janssen Biotech, Inc.Inventors: Jarrat Jordan, Sun-Yung Jung, Robert T. Sarisky, Jessica Schreiter
-
Publication number: 20140342920Abstract: The disclosure provides a method of identifying a subject as having B-cell non-Hodgkin lymphoma (NHL) such as testing a sample from a subject for a mutation in one or more biomarkers. Also described are methods of classifying or monitoring a subject having, or suspected of having, B-cell non-Hodgkin lymphoma comprising testing the same for a mutation in one or more biomarkers.Type: ApplicationFiled: May 20, 2014Publication date: November 20, 2014Applicant: British Columbia Cancer Agency BranchInventors: Ryan D. Morin, Marco A. Marra, Andrew J. Mungall, Martin Hirst, Maria Mendez-Lago, Randy D. Gascoyne, Joseph M. Connors
-
Publication number: 20140341810Abstract: Provided herein are antagonists or binding agents of an abnormal vasopressin receptor V2 (e.g., AbnV2), such as antibodies and antigen-binding portions thereof specific for the receptor, for identifying and targeting cancer cells expressing such abnormal vasopressin receptor V2. Additionally provided are methods of using said antagonists or binding agents, for example, to image cancer cells or in biological samples, or diagnose cancers, both in vivo and in vitro. The antagonists or binding agents may also be used for treating patients suffering from a cancer expressing the abnormal vasopressin receptor V2, such as small cell lung cancer (SCLC), breast cancer, or ovarian cancer.Type: ApplicationFiled: May 12, 2014Publication date: November 20, 2014Applicant: WOOMERA THERAPEUTICSInventors: William G. North, Roy H.L. Pang
-
Patent number: 8889374Abstract: The present invention relates to recombinant factor H and variants and conjugates thereof and methods of their production, as well as uses and methods of treatment involving the materials.Type: GrantFiled: December 23, 2010Date of Patent: November 18, 2014Assignee: University Court of the University of EdinburghInventors: Christoph Schmidt, Paul N. Barlow, Anna Richards
-
Patent number: 8889597Abstract: The present invention provides nucleic acids and peptides, and methods of using the nucleic acids and peptides to identify subjects at risk for a TDP-43 proteinopathy. The invention also provides for an army comprising the nucleic acids and peptides of the invention.Type: GrantFiled: January 30, 2009Date of Patent: November 18, 2014Assignee: Washington UniversityInventors: Nigel J. Cairns, Robert H Baloh, Alan Pestronk, Michael A. Gitcho, Alison M. Goate
-
Patent number: 8889845Abstract: Compositions and methods for the detection, diagnosis and treatment of BVDV and other viruses are provided.Type: GrantFiled: June 3, 2010Date of Patent: November 18, 2014Assignee: University of WyomingInventors: Thomas R. Hansen, Kathleen J. Austin, Alberto van Olphen, Lea A. Rempel
-
Patent number: 8889408Abstract: HDART binds with HDAC (histone deacetylase) and functions as a repressor. HDART directly binds with Skip, which functions as a transcription co-activator of nuclear receptors, to repress the transcription by the nuclear receptor. Moreover, HDART is a transcription co-repressor of nuclear receptors, and binds with HDAC wherein transcription can be strongly repressed through the histone deacetylization of HDAC. On the other hand, a dominant negative peptide of HDART can be obtained, and it has been confirmed that, in contrast with the full-length HDART protein, this peptide activates transcription. In particular, the ability of this peptide to activate transcription by the retinoic acid receptor exceeds that of all-trans retinoic acid (ATRA).Type: GrantFiled: November 15, 2011Date of Patent: November 18, 2014Assignee: Sony CorporationInventors: Shuki Mizutani, Takayuki Yamada
-
Publication number: 20140335053Abstract: The present invention discloses the identification and isolation of novel MHC class II epitopes derived from the cancer antigen, NY ESO-1. The novel MHC class II epitopes from NY-EsO-1 are recognized by CD4+ T lymphocytes in an HLA class II restricted manner, in particular HLA-DR or HLA-DP restricted. The products of the gene are promising candidates for immunotherapeutic strategies for the prevention, treatment and diagnosis of patients with cancer.Type: ApplicationFiled: May 22, 2014Publication date: November 13, 2014Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Rong-Fu Wang, Steven A. Rosenberg, Gang Zeng
-
Publication number: 20140336126Abstract: The invention relates to Optineurin-derived polypeptide(s) consisting of a polypeptidic sequence disclosed in SEQ ID no2, which represents the portion of the wild-type human Optineurin protein sequence from its amino-acid residue 131 to its amino-acid residue 297, or having a polypeptidic sequence encompassing the polypeptidic sequence disclosed in SEQ ID no2, or having a polypeptidic sequence derived from the polypeptidic sequence disclosed in SEQ ID no2 to the exclusion of the wild-type Optineurin protein. The polypeptide(s) of the invention retain one, any combination of two, or three of the following functional properties: the capacity to bind Rab8 protein, when the latter are associated with the Golgi apparatus of a cell, the capacity to bind MYPT1 protein, when said protein is engaged in a Myosin-Phosphatase (MP) complex, the capacity to be phosphorylated by Plk1.Type: ApplicationFiled: December 18, 2012Publication date: November 13, 2014Inventors: Robert Serge Weil, David Kachaner, Josina Côrte-Real Filipe, Emmanuel François Laplantine, Alain Israël
-
Publication number: 20140335108Abstract: The present invention is directed to compositions and methods to treat an autoimmune disease in a subject, comprising an insulin-like 6 (Insl6) agent, such as an Insl6 polypeptide or variant or fragment thereof, or a nucleic acid encoding Insl6 poly peptide or variant or fragment thereof. Aspects of the present invention relate to use of Insl6 agents to reduce T-regulatory (Treg) cells in the subject and to reduce pro-inflammatory cytokines in a subject with an autoimmune disease such as a muscle autoimmune disease. The present invention also relates to methods and kits for the treatment of autoimmune diseases in a subject, and methods to diagnose a subject with an autoimmune disease such as myositis.Type: ApplicationFiled: December 12, 2012Publication date: November 13, 2014Inventors: Kenneth Walsh, Ling Zeng
-
Patent number: 8883134Abstract: The present disclosure provides a fusion protein comprising IL-1 receptor antagonist fused to a hybrid Fc. Particularly the present disclosure relates to a fusion protein comprising IL-1 receptor antagonist fused to a human immunoglobulin hybrid Fc fragment. In one embodiment, the hybrid Fc fragment comprises IgD and IgG4. Also provided is a pharmaceutical composition comprising the present fusion protein, which are useful for treating autoimmune disease including rheumatoid arthritis, inflammatory bowel disease (Crohn's disease, ulcerative colitis), psoriasis and diabetes and the like. The present fusion protein with excellent efficacy and reduced side effects is qualified for clinical development as therapeutic antibodies to treat autoimmune disease.Type: GrantFiled: October 19, 2011Date of Patent: November 11, 2014Assignees: Handok Pharmaceuticals, Inc., Genexine, Inc.Inventors: Young Gyu Cho, Hye Jeong Shin, Woon Young Lee, Woo Ick Jang
-
Publication number: 20140328791Abstract: Conjugates of an IL-2 moiety and one or more nonpeptidic, water-soluble polymers are provided. Typically, the nonpeptidic, water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, methods of administering compositions to an individual, nucleic acid sequences, expression systems, host cells, and methods for preparing IL-moieties.Type: ApplicationFiled: November 11, 2011Publication date: November 6, 2014Inventors: Mary J. Bossard, Cherie F. Ali, Xiaofeng Liu, Deborah H. Charych, Harold Zappe, Yujun Wang, Jicai Huang
-
Publication number: 20140329255Abstract: The present invention relates to the discovery that the T1R receptors assemble to form functional taste receptors. Particularly, it has been discovered that co-expression of T1R1 and T1R3 results in a taste receptor that responds to umami taste stimuli, including monosodium glutamate. Also, it has been discovered that co-expression of the T1R2 and T1R3 receptors results in a taste receptor that responds to sweet taste stimuli including naturally occurring and artificial sweeteners. Also the present invention relates to the use of hetero-oligomeric taste receptors comprising T1R1/T1R3 and T1R2/T1R3 in assays to identify compounds that respectively respond to umami taste stimuli and sweet taste stimuli.Type: ApplicationFiled: May 14, 2014Publication date: November 6, 2014Applicant: SENOMYX, INC.Inventors: Mark ZOLLER, Xiaodong LI, Lena STASZEWSKI, Shawn O'CONNELL, Sergey ZOZULYA, Jon Elliot ADLER, Hong XU, Fernando ECHEVERRI
-
Publication number: 20140328831Abstract: The present invention relates generally to tissue differentiation factor (TDF) analogs. More specifically, the invention relates to structure-based methods and compositions useful in designing, identifying, and producing molecules which act as functional modulators of TDF-like receptors. The invention further relates to methods of detecting, preventing, and treating TDF-associated disorders.Type: ApplicationFiled: March 24, 2014Publication date: November 6, 2014Inventors: William D. Carlson, Peter C. Keck
-
Publication number: 20140329757Abstract: A novel isolated protein, referred to herein as “caltubin”, is provided. Caltubin promotes axonal regeneration, and prevents or at least reduces axonal retraction in neurons.Type: ApplicationFiled: October 12, 2012Publication date: November 6, 2014Applicant: University of TorontoInventors: Zhong-Ping Feng, Nasrin Najatbakhsh, Ronald E. Van Kasteren, August B. Smit, Hong-Shou Sun, Andrew Barszczyk
-
Publication number: 20140329250Abstract: The invention provides calcium-binding photoproteins which can detect light emission with a higher sensitivity. The proteins of the invention comprising the amino acid sequence of SEQ ID NO: 2 can be used for the detection and measurement of calcium ions. The proteins of the invention are useful as reporter proteins, luminescent markers, etc. The polynucleotides of the invention are useful as reporter genes, etc.Type: ApplicationFiled: May 30, 2014Publication date: November 6, 2014Inventors: Satoshi INOUYE, Yuiko SAHARA
-
Patent number: 8878002Abstract: The present invention relates to DYAD genes, mutants thereof, and use of them for making plants that retain heterozygosity of the female parent plant. The invention also encompasses plants, plant tissues, and seeds of plants that have a dyad phenotype and so retain heterozygosity of the female parent, either constitutively or conditionally. The invention is useful for propagating desired hybrid phenotypes in a manner of an apomictic plant and for increasing the ploidy of a plant genotype, which may result in plants having increased biomass.Type: GrantFiled: November 13, 2006Date of Patent: November 4, 2014Assignee: Council of Scientific and Industrial ResearchInventors: Imran Siddiqi, Maruthachalam Ravi, Mohan Prem Anand Marimuthu
-
Patent number: 8877476Abstract: A soluble and stable form of 5-lipoxygenase (5-LOX) has been made, 5-Lox is the enzyme which initiates leukotriene biosynthesis by catalyzing the two-step transformation of arachidomc acid to leukotriene A4 (LTA4). The soluble and stable 5-LOX is suitable for a number of applications, including, but not limited to, high throughput screening of 5-LOX inhibitors, structural analysis of the enzyme's active site, designing inhibitors based on the three-dimensional structure of the enzyme's active site, and synthesis of LTA4. Using Stable-5-LOX, the crystal structure for 5-LOX has been resolved and the amino acids defining the active site determined.Type: GrantFiled: May 31, 2011Date of Patent: November 4, 2014Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Marcia E. Newcomer, Sue G. Bartlett, Nathaniel C. Gilbert
-
Publication number: 20140322730Abstract: An isolated polypeptide comprising an amino acid sequence selected from amino acids 506-582 of SV2A, wherein position 573 is N and is glycosylated, or amino acids 449-525 of SV2B, wherein position 516 is N and is glycosylated. The present invention also provides an antibody that binds specifically to the polypeptide, an isolated nucleic acid comprising a polynucleotide that encodes the polypeptide; a method for reducing BoNT/E toxicity in an animal; a method for identifying an agent that blocks or inhibits binding between BoNT/E and an SV2A or SV2B protein; a method for monitoring synaptic vesicle endo- or exocytosis, a method for specifically delivering a chemical entity to a cell which has a specific receptor to a BoNT toxin.Type: ApplicationFiled: May 20, 2014Publication date: October 30, 2014Applicant: Wisconsin Alumni Research FoundationInventors: Edwin R. Chapman, Min Dong
-
Publication number: 20140322812Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.Type: ApplicationFiled: April 24, 2014Publication date: October 30, 2014Applicant: Intrexon CorporationInventors: Subba Reddy PALLI, Mohan Basavaraju KUMAR
-
Publication number: 20140325702Abstract: The present invention is directed to controlling plant pest infestation, and particularly plant nematode infestation, by inhibiting one or more biological functions in the plant pest. The invention discloses methods and compositions for use in controlling plant pest infestation by providing one or more different recombinant double stranded RNA molecules in the diet of the pest in order to achieve a reduction in pest infestation through suppression of pest gene expression. The invention is also directed to methods for making transgenic plants that express the double stranded RNA molecules, to methods for detecting cells comprising the disclosed sequences, and to methods for detecting the disclosed sequences in biological samples.Type: ApplicationFiled: December 29, 2011Publication date: October 30, 2014Inventors: Andrey A. Boukharov, Zijin Du, Liang Guo, David K. Kovalic, Maolong Lu, James P. McCarter, Nancy M. Miller, Mark Vaudin, Deryck Jeremy Williams, Wei Wu
-
Publication number: 20140322205Abstract: Dominant negative (DN) variants of transcriptional enhancer factor 1-related (RTEF-1) are described. DN RTEF-1 polypeptides may be directly targeted to cells or delivered in nucleic acid expression vectors to alter cellular transcription. Methods for inhibiting VEGF production and thereby treating angiogenic disorders such as cancer are described. For example, in certain aspects, DN RTEF-1 may be used to treat angiogenic disorders of the eye such as age related macular degeneration (AMD).Type: ApplicationFiled: May 5, 2014Publication date: October 30, 2014Applicant: RESEARCH DEVELOPMENT FOUNDATIONInventors: J. Timothy STOUT, Trevor J. MCFARLAND, Binoy APPUKUTTAN
-
Publication number: 20140323396Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.Type: ApplicationFiled: January 29, 2014Publication date: October 30, 2014Applicant: AMGEN INC.Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
-
Publication number: 20140323706Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: ApplicationFiled: March 25, 2013Publication date: October 30, 2014Applicant: GENENTECH, INC.Inventors: Jian Chen, Ellen Filvaroff, Sherman Fong, Audrey Goddard, Paul Godowski, Christopher Grimaldi, Austin Gurney, Hanzhong Li, Kenneth Hillan, Daniel Tumas, Menno VanLookeren, Richard Vandlen, Colin Watanabe, P. Mickey Williams, William I. Wood, Daniel Yansura
-
Publication number: 20140322161Abstract: The present invention relates to a pharmaceutical composition comprising, by way of active ingredient, at least one polypeptide comprising, or constituted by a sequence constituted by at least 8 contiguous amino acids and from at the most 30 contiguous amino acids chosen from within the interleukin-6 sequence and from at the most 30 contiguous amino acids chosen from within the complete IL-6 sequence.Type: ApplicationFiled: August 9, 2012Publication date: October 30, 2014Applicant: PEPTINOV SASInventors: Lucille Desallais, Mattieu Montes, Jean-Francois Zagury
-
Patent number: 8871714Abstract: The invention relates to hyperglycosylated human coagulation factor IX polypeptides, to processes for preparing said polypeptides, to pharmaceutical compositions comprising said polypeptides and to the use of the compounds for the treatment of diseases alleviated by human coagulation factor IX, in particular, but not exclusively hemophilia.Type: GrantFiled: December 21, 2012Date of Patent: October 28, 2014Assignee: Novo Nordisk Health Care AGInventors: Gert Bolt, Claus Kristensen
-
Publication number: 20140315822Abstract: The invention relates to polypeptides containing a cytoplasmic domain ending with a MAST-2 binding domain, from 11 to 13 residues, the first two residues of which are S and W, and the last four residues of which are Q, T, R and L, said polypeptides presenting a high affinity for the PDZ domain of the human MAST2 protein. The invention also relates to polynucleotides, vectors, lentiviral particles, cells as well as compositions comprising the same. The invention is also directed to the use of said polypeptides, polynucleotides, vectors, lentiviral particles, cells and compositions in the treatment and/or prevention of a disease, disorder or condition, which alters the Central Nervous System (CNS) and/or the Peripheral Nervous System (PNS). The invention also concerns molecular signatures of cellular genes to determine the neurosurvival and/or neuroprotection activity of a molecule.Type: ApplicationFiled: November 7, 2012Publication date: October 23, 2014Applicant: CENTRE NATIONAL DE LA RECHERCE SCIENTIFIQUEInventors: Christophe Prehaud, Monique Lafon, Nicolas Wolff, Zakir Khan, Elouan Terrien, Sandrine Vitry
-
Publication number: 20140314758Abstract: Immunogenic peptides from tumor associated stromal cell antigens, including combinations of such peptides, are disclosed herein. In some examples the peptides are useful for methods of eliciting an immune response. In additional examples the peptides are useful for methods of treating cancer. Methods for decreasing vascularization of a tumor using a Protein Delta Homolog 1 (DLK1) protein or a nucleic acid encoding the protein are also disclosed.Type: ApplicationFiled: November 15, 2012Publication date: October 23, 2014Applicant: University of Pittsburgh- Of the Commonwealth System of Higher EducationInventors: Walter J. Storkus, Anamika Bose, Jennifer Lynn Taylor, Xi Zhao, Devin B. Lowe
-
Publication number: 20140314768Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.Type: ApplicationFiled: December 6, 2013Publication date: October 23, 2014Applicant: CELERA CORPORATIONInventors: Steve RUBEN, Karen VAN ORDEN, Bruno DOMON, Candy LEE, Tao HE, Mehdi MESRI, Elizabeth JOSELOFF, Katherine MCKINNON, Paul MOORE, Charles BIRSE
-
Publication number: 20140315825Abstract: The present invention relates to a composition for preventing or treating cancer comprising Wnt decoy receptor. The composition of the present invention or the expression product thereof inhibits cancer generation, growth, proliferation and metastasis, and induces apoptosis of cancer cells, by binding to Wnt ligand and blocking ligand-receptor interactions, therefore may be effectively used as an anti-cancer agent.Type: ApplicationFiled: August 16, 2012Publication date: October 23, 2014Applicant: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITYInventors: Chae Ok Yun, Jung-Sun Lee
-
Publication number: 20140314831Abstract: Disclosed is a recombinant polypeptide for facilitating membrane fusion. The recombinant polypeptide having a sequence with at least 80% sequence identity with the ectodomain of p14 fusion-associated small transmembrane (FAST) protein and having a functional myristoylation motif, a transmembrane domain from a FAST protein and a sequence with at least 80% sequence identity with the endodomain of p15 FAST protein. A targeting ligand can be added to the recombinant polypeptide for selective fusion. The recombinant polypeptide can be included in the membrane of a liposome, or the like, to facilitate the delivery of bioactive compounds, such as siRNA, or the recombinant polypeptide can be mixed with a lipid carrier and added to cultured cells to induce cell-cell fusion and heterokaryon formation.Type: ApplicationFiled: September 29, 2011Publication date: October 23, 2014Applicant: Innovascreen Inc.Inventors: Roy Duncan, John Lewis, Roberto Justo De Antueno, Rae-Lynn Nesbitt, Eileen Kathryn Clancy